Mangoceuticals, Inc.
MGRX
$2.04
$0.000.00%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Revenue | -48.95% | -56.96% | -45.60% | 15.58% | 112.61% |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -48.95% | -56.96% | -45.60% | 15.58% | 112.61% |
Cost of Revenue | -29.24% | -75.34% | -49.60% | 72.64% | 53.33% |
Gross Profit | -57.87% | -43.83% | -42.81% | -19.86% | 157.69% |
SG&A Expenses | 47.40% | -26.96% | -6.09% | -11.33% | -0.94% |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 45.30% | 0.07% | -8.54% | -2.19% | 20.26% |
Operating Income | -54.37% | -6.28% | 2.65% | 3.32% | -15.44% |
Income Before Tax | -104.41% | 24.12% | -11.13% | -4.70% | 7.55% |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -104.41% | 24.12% | -11.13% | -4.70% | 7.55% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -104.40% | 24.13% | -11.10% | -4.68% | 7.55% |
EBIT | -54.37% | -6.28% | 2.65% | 3.32% | -15.44% |
EBITDA | -36.10% | 25.69% | 2.27% | 3.19% | -15.48% |
EPS Basic | 29.93% | 45.01% | 41.44% | 36.74% | 55.93% |
Normalized Basic EPS | 29.92% | 62.02% | 41.44% | 36.74% | 55.93% |
EPS Diluted | 29.93% | 45.01% | 41.44% | 36.74% | 55.93% |
Normalized Diluted EPS | 29.92% | 62.02% | 41.44% | 36.74% | 55.93% |
Average Basic Shares Outstanding | 191.70% | 99.73% | 89.69% | 65.48% | 109.78% |
Average Diluted Shares Outstanding | 191.70% | 99.73% | 89.69% | 65.48% | 109.78% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |